مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

947
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

0
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

CONVENTIONAL CHEMORADIATION WITH CISPLATIN VERSUS HEMORADIATION WITH CISPLATIN PLUS GEMCITABINE IN UTERINE CERVICAL CANCER

Pages

  19-26

Abstract

 Background and Objective: Due to high mortality and morbidity of the CERVICAL CANCER we decided to compare benefits and advers effects of GEMCITABINE plus conventional CHEMORADIATION with conventional CHEMORADIATION with CISPLATIN alone in Imam Hossein hospital, in Tehran, Iran.Materials and Methods: This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: (A) Conventional concurrent CHEMORADIATION with CISPLATIN (N=18) versus(B) concurrent CHEMORADIATION with CISPLATIN plus gemicitabine (N=16). The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test.Results: Despite increasing of complete response rate with adding GEMCITABINE to conventional treatment (81.2% vs. 66.7%), the difference in two groups was not statistically significant.Conclusion: This study indicated that the addition of gemicatabine to conventional CHEMORADIATION with CISPLATINrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    AMERI, AHMAD, TABATABAEIFAR, MORTEZA, KHANDOUZI, S.R., HATAMI, E., MOJIR SHEYBANI, KH., & ALIDOUSTI, A.A.. (2008). CONVENTIONAL CHEMORADIATION WITH CISPLATIN VERSUS HEMORADIATION WITH CISPLATIN PLUS GEMCITABINE IN UTERINE CERVICAL CANCER. JOURNAL OF GORGAN UNIVERSITY OF MEDICAL SCIENCES, 10(3 (27)), 19-26. SID. https://sid.ir/paper/79613/en

    Vancouver: Copy

    AMERI AHMAD, TABATABAEIFAR MORTEZA, KHANDOUZI S.R., HATAMI E., MOJIR SHEYBANI KH., ALIDOUSTI A.A.. CONVENTIONAL CHEMORADIATION WITH CISPLATIN VERSUS HEMORADIATION WITH CISPLATIN PLUS GEMCITABINE IN UTERINE CERVICAL CANCER. JOURNAL OF GORGAN UNIVERSITY OF MEDICAL SCIENCES[Internet]. 2008;10(3 (27)):19-26. Available from: https://sid.ir/paper/79613/en

    IEEE: Copy

    AHMAD AMERI, MORTEZA TABATABAEIFAR, S.R. KHANDOUZI, E. HATAMI, KH. MOJIR SHEYBANI, and A.A. ALIDOUSTI, “CONVENTIONAL CHEMORADIATION WITH CISPLATIN VERSUS HEMORADIATION WITH CISPLATIN PLUS GEMCITABINE IN UTERINE CERVICAL CANCER,” JOURNAL OF GORGAN UNIVERSITY OF MEDICAL SCIENCES, vol. 10, no. 3 (27), pp. 19–26, 2008, [Online]. Available: https://sid.ir/paper/79613/en

    Related Journal Papers

    Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button